SET antibody (SET Nuclear Oncogene)

Details for Product anti-SET Antibody No. ABIN265241, Supplier: Log in to see
  • 2PP2A
  • I2PP2A
  • IPP2A2
  • TAF-I
  • 2610030F17Rik
  • 5730420M11Rik
  • AA407739
  • I-2PP2A
  • StF-IT-1
  • SET translocation
  • SET nuclear oncogene
  • LOC403555
  • SET
  • Set
anti-Human SET antibody for Flow Cytometry
Western Blotting (WB)
Log in to see
Supplier Product No.
Log in to see

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Immunogen Synthetic peptide derived from the human SET protein
Isotype IgG
Specificity This antibody detects I2PP2A / SET, widely expressed. Low levels in quiescent cells during serum starvation, contact inhibition or differentiation. Highly expressed in Wilms' tumor.
Purification Affinity chromatography
Alternative Name SET / I2PP2A (SET Antibody Abstract)
Background Human SET was originally identified as part of the SET-CAN fusion gene produced by a somatic translocation event in a patient with acute undifferentiated leukemia. In developing kidney, SET is highly expressed in the zone of nephron morphogenesis. SET has been shown to be a potent and specific inhibitor of protein phosphatase 2A, a family of major serine/threonine phosphatases involved in regulating cell proliferation and differentiation. SET is also involved in the regulation of renal cell proliferation and tumorigenesis. SET mRNA expression is markedly reduced in cells rendered quiescent by serum starvation, contact inhibition, or differentiation. SET protein expression is also much greater in developing rat and human kidney than in fully differentiated, mature kidney. High levels of SET mRNA and SET protein expression arefound in Wilms' tumor, but not in renal cell carcinoma, adult polycystic kidney disease or in transitional cell carcinoma.Synonyms: I-2PP2A, IGAAD, Inhibitor of granzyme A-activated DNase, PHAPII, Phosphatase 2A inhibitor I2PP2A, TAF-I, Template-activating factor I
Gene ID 6418
NCBI Accession NP_001116293
UniProt H0UI37
Pathways Apoptosis
Application Notes Western blot (1: 400 dilution).
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Buffer Phosphate buffered saline with 0.08 % sodium azide
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice Avoid repeated freezing and thawing.
Storage -20 °C
Storage Comment Store the product (in aliquots) at -20 °C to -70 °C. Can be shipped at 2 - 8 °C.
Product cited in: Shih, Shih, Lee, Huang, Wang, Chen, Tsai: "Particle size distributions and health-related exposures of polychlorinated dibenzo-p-dioxins and dibenzofurans (PCDD/Fs) of sinter plant workers." in: Chemosphere, 2009 (PubMed).

Background publications Molina, Horn, Tang, Mathivanan, Pandey: "Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 104, Issue 7, pp. 2199-204, 2007 (PubMed).

Olsen, Blagoev, Gnad, Macek, Kumar, Mortensen, Mann: "Global, in vivo, and site-specific phosphorylation dynamics in signaling networks." in: Cell, Vol. 127, Issue 3, pp. 635-48, 2006 (PubMed).

Kim, Sprung, Chen, Xu, Ball, Pei, Cheng, Kho, Xiao, Xiao, Grishin, White, Yang, Zhao: "Substrate and functional diversity of lysine acetylation revealed by a proteomics survey." in: Molecular cell, Vol. 23, Issue 4, pp. 607-18, 2006 (PubMed).

Tsujio, Zaidi, Xu, Kotula, Grundke-Iqbal, Iqbal: "Inhibitors of protein phosphatase-2A from human brain structures, immunocytological localization and activities towards dephosphorylation of the Alzheimer type hyperphosphorylated tau." in: FEBS letters, Vol. 579, Issue 2, pp. 363-72, 2005 (PubMed).

Gerhard, Wagner, Feingold, Shenmen, Grouse, Schuler, Klein, Old, Rasooly, Good, Guyer, Peck, Derge, Lipman, Collins, Jang, Sherry, Feolo, Misquitta, Lee, Rotmistrovsky, Greenhut, Schaefer, Buetow et al.: "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). ..." in: Genome research, Vol. 14, Issue 10B, pp. 2121-7, 2004 (PubMed).

Fan, Beresford, Oh, Zhang, Lieberman: "Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor." in: Cell, Vol. 112, Issue 5, pp. 659-72, 2003 (PubMed).

Seo, McNamara, Heo, Turner, Lane, Chakravarti: "Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein." in: Cell, Vol. 104, Issue 1, pp. 119-30, 2001 (PubMed).

Minakuchi, Kakazu, Gorrin-Rivas, Abe, Copeland, Ueda, Adachi: "Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET." in: European journal of biochemistry / FEBS, Vol. 268, Issue 5, pp. 1340-51, 2001 (PubMed).

Li, Makkinje, Damuni: "Molecular identification of I1PP2A, a novel potent heat-stable inhibitor protein of protein phosphatase 2A." in: Biochemistry, Vol. 35, Issue 22, pp. 6998-7002, 1996 (PubMed).

Nagata, Kawase, Handa, Yano, Yamasaki, Ishimi, Okuda, Kikuchi, Matsumoto: "Replication factor encoded by a putative oncogene, set, associated with myeloid leukemogenesis." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 92, Issue 10, pp. 4279-83, 1995 (PubMed).

von Lindern, van Baal, Wiegant, Raap, Hagemeijer, Grosveld: "Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene." in: Molecular and cellular biology, Vol. 12, Issue 8, pp. 3346-55, 1992 (PubMed).